Menu
Recruiting NCT02134574

Prospective Cohort With Hemopathy in Languedoc-Roussillon

— Observational Hematologic Malignancy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: hematologic malignancy.
Who it may be relevant to
Registry conditions: Hematologic Malignancy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon

Overview

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.

Detailed description

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy in LR.

Interventions

  • Biological hematologic malignancy
    hematologic malignancy with a sampling of blood

Primary outcome measures

  • Survival with 2 years [Time frame: 2 years]
Secondary outcome measures (2)
  • Survival with 5 years [Time frame: 5 years]
  • Survival with 10 years [Time frame: 10 years]

Eligibility criteria

Inclusion criteria

  • Age over 18
  • Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent
  • Having signed an informed consent
  • Affiliated with a social security scheme

Exclusion criteria

  • Minor or major protected
  • Patients who have received treatment for hematological pathology

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • Hematology department - UHMontpellier Saint éloi — Montpellier

Identifiers

NCT: NCT02134574 · 9011

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗